Navigation Links
Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
Date:7/14/2015

BROOMFIELD, Colo., July 14, 2015 /PRNewswire/ -- Accera, Inc. today announced that it has achieved 75% enrollment for its NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of Alzheimer's disease. The study has a total planned enrollment of approximately 480 patients and is the first of two Phase 3 trials of AC-1204, an investigational new drug designed to address the metabolic defect of the brain observed in Alzheimer's patients.

"The NOURISH AD trial is progressing well, and we expect to complete enrollment mid-next year," said Accera's President and CEO, Dr. Charles Stacey. "The repeated failure of pipeline drugs for Alzheimer's disease emphasizes the need to explore new mechanisms in order to identify new options for patients. The NOURISH AD study represents a differentiated approach to tackling this disease."

"Instead of addressing amyloid or tau, AC-1204 addresses the metabolic defects seen in the disease," added Samuel Henderson, Ph.D., Accera's vice president of research and development and the study's director. "The only way we can beat Alzheimer's is by testing new drugs in studies like NOURISH AD. We are grateful for the support of all of the patients, caregivers and investigators who have joined us in the effort to find new treatments."

About the NOURISH AD Phase 3 Clinical Study

NOURISH AD is a 26-week, double-blind, randomized, placebo-controlled, parallel-group study investigating the effects of daily administration of AC-1204 in subjects with mild to moderate Alzheimer's disease, with an optional 26-week open-label extension. Conducted at up to 90 sites, the study is currently enrolling patients with an anticipated total of approximately 480 enrolled. The primary and key secondary endpoints will examine the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and global function as measured by the Alzheimer's Disease Study Cooperative Study – Clinicial Global Impression of Change (ADCS-CGIC) after 26 weeks among non-carriers of the epsilon 4 variant of the gene apolipoprotein E (APOE4). The study will also evaluate activities of daily living, resource utilization and quality of life among subjects with mild-to-moderate Alzheimer's.

For more information, visit https://www.AD-trial.com

About Accera

Accera, Inc. is a clinical-stage biotechnology company based in Broomfield, Colorado, developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. From its roots in developing a marketed product, Axona®, Accera has advanced to the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease.

For more information, visit www.accerapharma.com.

Accera Media Contacts:                                                  

Russo Partners LLC 

Todd Davenport, Ph.D.
(212) 845-4235                                                        
todd.davenport@russopartnersllc.com

David Schull                                                             
(212) 845-4271
(858) 717-2310 Mobile                                                                                david.schull@russopartnersllc.com                       


'/>"/>
SOURCE Accera, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Accera Appoints Charles Stacey, M.D., as President and CEO
2. Enrollment in Relmada Therapeutics Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
3. Report: Proteomics Research Market Reaches $1.6 Billion
4. Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion
5. Kalorama: Global Medical Device Market Reaches $360 Billion
6. Transvaginal Mesh Settlement News: Boston Scientific Reaches First TVM Settlement, Says Lawsuitsettlementnews.com
7. Medicare Advantage Enrollment Reaches 17 Million According to Mark Farrah Associates
8. Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications
9. Block & Leviton LLP Investigates Hospira, Inc. for Possible Breaches of Fiduciary Duty in Connection with Their Proposed Acquisition by Pfizer Inc.
10. Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia
11. MediciGlobals Alzheimers Community Reaches 200,000 likes and more than half a million weekly visitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2018)... ... ... It’s time to start thinking about New Year’s resolutions. Women’s Excellence ... to maintain a healthy lifestyle. Women’s Excellence is committed to helping patients reach ... to document goals, discuss expected results, and begin a diet regimen and exercise regimen. ...
(Date:12/13/2018)... WASHINGTON (PRWEB) , ... December 13, 2018 , ... ... who work closely with patients from all 50 states and 35 countries around the ... Sandy Li, M.D., to the practice. Dr. Li will see Mandarin and ...
(Date:12/13/2018)... REDWOOD CITY, Calif. (PRWEB) , ... December 13, ... ... company transforming infectious disease diagnostics with genomics, announced today the results of an ... The early findings showed that the Karius® Test, a non-invasive blood test that ...
Breaking Medicine Technology:
(Date:12/18/2018)... ... December 18, 2018 , ... Ethos Veterinary Health (“Ethos”) ... to identify and develop new cancer therapeutics that are uniquely suited to prevent ... align cancer’s major unmet therapeutic need (i.e. preventing cancer recurrence or metastasis) with ...
(Date:12/16/2018)... ... December 15, 2018 , ... Solo Printing, a Miami-based commercial printing company, ... non-profit who connects communities around Latin America with access to clean water and sanitation. ... help improve health and the overall quality of life in rural communities. The non-profit ...
(Date:12/14/2018)... N.Y. (PRWEB) , ... December 14, 2018 , ... ... its Baby Powder. The company, which has pending lawsuits that claim its talc ... concern over positive test results for asbestos in its baby powder. The documents ...
(Date:12/14/2018)... ... 14, 2018 , ... The Parenteral Drug Association (PDA) today announced the results ... the fall of 2018, PDA’s 10,500 members had an opportunity to participate in the ... to the PDA Board of Directors for three-year terms starting Jan. 1, 2019: , ...
(Date:12/14/2018)... ... 14, 2018 , ... Bathing can be very dangerous for seniors and people ... occur in the bathroom for seniors 65 and older, according to The National Council ... 2005, manufacturing or distributing walk-in tubs and bath accessories. Following these tips may help ...
Breaking Medicine News(10 mins):